BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci. 2020;21:5097. [PMID: 32707678 DOI: 10.1038/s41575-019-0226-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 29.0] [Reference Citation Analysis]
Number Citing Articles
1 Simbrunner B, Trauner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther 2021;54:1243-62. [PMID: 34555862 DOI: 10.1111/apt.16602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Huo JH, Wang XY, Gong L, Gu X. Role of regulatory B cells in autoimmune diseases of the digestive system. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 486-492 [DOI: 10.11569/wcjd.v28.i12.486] [Reference Citation Analysis]
3 Wu H, Chen C, Ziani S, Nelson LJ, Ávila MA, Nevzorova YA, Cubero FJ. Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells 2021;10:1107. [PMID: 34062960 DOI: 10.3390/cells10051107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut 2021;70:1989-2003. [PMID: 34266966 DOI: 10.1136/gutjnl-2020-322362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
5 Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet 2020;396:1915-26. [PMID: 33308474 DOI: 10.1016/S0140-6736(20)31607-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
6 Zhao J, Ran M, Yang T, Chen L, Ji P, Xu X, Zhang L, Sun S, Liu X, Zhou S, Zhou L, Zhang J. Bicyclol Alleviates Signs of BDL-Induced Cholestasis by Regulating Bile Acids and Autophagy-Mediated HMGB1/p62/Nrf2 Pathway. Front Pharmacol 2021;12:686502. [PMID: 34366845 DOI: 10.3389/fphar.2021.686502] [Reference Citation Analysis]
7 Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, Shaikh F, Bainbridge JD, Parmar DV, Chalasani NP. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol 2021:S0168-8278(21)02023-7. [PMID: 34487750 DOI: 10.1016/j.jhep.2021.08.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor SS, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byan J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF; PBC Consortia., Canadian PBC Consortium., Chinese PBC Consortium., Italian PBC Study Group., Japan-PBC-GWAS Consortium., US PBC Consortium., UK-PBC Consortium. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol 2021;75:572-81. [PMID: 34033851 DOI: 10.1016/j.jhep.2021.04.055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
9 Li S, Wang C, Zhang X, Su W. Cytochrome P450 Omega-Hydroxylase 4a14 Attenuates Cholestatic Liver Fibrosis. Front Physiol 2021;12:688259. [PMID: 34135776 DOI: 10.3389/fphys.2021.688259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kremer AE, Mayo MJ, Hirschfield G, Levy C, Bowlus CL, Jones DE, Steinberg A, McWherter CA, Choi YJ. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver Int 2021. [PMID: 34403559 DOI: 10.1111/liv.15039] [Reference Citation Analysis]
11 Martínez-garcía J, Molina A, González-aseguinolaza G, Weber ND, Smerdou C. Gene Therapy for Acquired and Genetic Cholestasis. Biomedicines 2022;10:1238. [DOI: 10.3390/biomedicines10061238] [Reference Citation Analysis]
12 Bauer A, Habior A, Wieszczy P, Gawel D. Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis. Diagnostics (Basel) 2021;11:587. [PMID: 33805158 DOI: 10.3390/diagnostics11040587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Molinaro A, Marschall HU. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders. Biochem Soc Trans 2022:BST20210658. [PMID: 35191955 DOI: 10.1042/BST20210658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang Y, Jiao Z, Chen M, Shen B, Shuai Z. Roles of Non-Coding RNAs in Primary Biliary Cholangitis. Front Mol Biosci 2022;9:915993. [DOI: 10.3389/fmolb.2022.915993] [Reference Citation Analysis]
15 Garcês Soares S, Mendes M, Rodrigues Carvalho S, Pereira Anjos D, Sá AJ. Primary Biliary Cholangitis: A Case of Underdiagnosis. Cureus 2021;13:e17716. [PMID: 34650890 DOI: 10.7759/cureus.17716] [Reference Citation Analysis]
16 Gerussi A, Paraboschi EM, Cappadona C, Caime C, Binatti E, Cristoferi L, Asselta R, Invernizzi P. The Role of Epigenetics in Primary Biliary Cholangitis. Int J Mol Sci 2022;23:4873. [PMID: 35563266 DOI: 10.3390/ijms23094873] [Reference Citation Analysis]
17 Tuominen I, Fuqua BK, Pan C, Renaud N, Wroblewski K, Civelek M, Clerkin K, Asaryan A, Haroutunian SG, Loureiro J, Borawski J, Roma G, Knehr J, Carbone W, French S, Parks BW, Hui ST, Mehrabian M, Magyar C, Cantor RM, Ukomadu C, Lusis AJ, Beaven SW. The Genetic Architecture of Carbon Tetrachloride-Induced Liver Fibrosis in Mice. Cell Mol Gastroenterol Hepatol 2021;11:199-220. [PMID: 32866618 DOI: 10.1016/j.jcmgh.2020.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Márquez A, Martín J. Genetic overlap between type 1 diabetes and other autoimmune diseases. Semin Immunopathol 2021. [PMID: 34595540 DOI: 10.1007/s00281-021-00885-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Berthier A, Johanns M, Zummo FP, Lefebvre P, Staels B. PPARs in liver physiology. Biochim Biophys Acta Mol Basis Dis 2021;1867:166097. [PMID: 33524529 DOI: 10.1016/j.bbadis.2021.166097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PSC, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021;218:e20200853. [PMID: 34495298 DOI: 10.1084/jem.20200853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells 2020;9:E875. [PMID: 32260126 DOI: 10.3390/cells9040875] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 24.5] [Reference Citation Analysis]
23 Taniki N, Nakamoto N, Chu PS, Ichikawa M, Teratani T, Kanai T. Th17 cells in the liver: balancing autoimmunity and pathogen defense. Semin Immunopathol 2022. [PMID: 35211777 DOI: 10.1007/s00281-022-00917-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Yan N, Yan T, Xia Y, Hao H, Wang G, Gonzalez FJ. The pathophysiological function of non-gastrointestinal farnesoid X receptor. Pharmacol Ther 2021;226:107867. [PMID: 33895191 DOI: 10.1016/j.pharmthera.2021.107867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci. 2020;21:5097. [PMID: 32707678 DOI: 10.1038/s41575-019-0226-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 29.0] [Reference Citation Analysis]
26 Yang Y, Zhao RC, Zhang F. Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives. Front Cell Dev Biol 2022;10:933565. [DOI: 10.3389/fcell.2022.933565] [Reference Citation Analysis]
27 Goyes D, Barba R, Medina-Morales E, Saberi B, Patwardhan V, Bonder A. Waitlist mortality in patients with autoimmune liver diseases. Ann Hepatol 2022;:100742. [PMID: 35835366 DOI: 10.1016/j.aohep.2022.100742] [Reference Citation Analysis]
28 Tang D, Cao F, Yan C, Fang K, Ma J, Gao L, Sun B, Wang G. Extracellular Vesicle/Macrophage Axis: Potential Targets for Inflammatory Disease Intervention. Front Immunol 2022;13:705472. [DOI: 10.3389/fimmu.2022.705472] [Reference Citation Analysis]
29 Ben Lamine Z, Ben Jazia I, Ben Ahmed M, Ben Slama A, Baccouche A, Slama F, Jemaa A, Ghedira I, Mankaï A. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis. Arab J Gastroenterol 2021:S1687-1979(21)00028-9. [PMID: 34090832 DOI: 10.1016/j.ajg.2021.05.006] [Reference Citation Analysis]
30 Han Y, Bian Z, Yang S, Wang C, Li L, Yang Y, Ansari AA, Gershwin ME, Zeng X, Lian Z, Zhao Z. Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis. Front Immunol 2022;13:860311. [DOI: 10.3389/fimmu.2022.860311] [Reference Citation Analysis]
31 Jiang T, Zhang HW, Wen YP, Yin YS, Yang LH, Yang J, Lan T, Tang CW, Yu JK, Tai WL, Yang JH. 5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance. Int Immunopharmacol 2021;96:107820. [PMID: 34162167 DOI: 10.1016/j.intimp.2021.107820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Ye X, Zhang T, Han H. PPARα: A potential therapeutic target of cholestasis. Front Pharmacol 2022;13:916866. [DOI: 10.3389/fphar.2022.916866] [Reference Citation Analysis]
33 Evangelakos I, Heeren J, Verkade E, Kuipers F. Role of bile acids in inflammatory liver diseases. Semin Immunopathol 2021. [PMID: 34236487 DOI: 10.1007/s00281-021-00869-6] [Reference Citation Analysis]
34 Chung BK, Øgaard J, Reims HM, Karlsen TH, Melum E. Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis. Hepatol Commun 2022. [PMID: 35726350 DOI: 10.1002/hep4.2001] [Reference Citation Analysis]
35 Sayaf K, Zanotto I, Russo FP, Gabbia D, De Martin S. The Nuclear Receptor PXR in Chronic Liver Disease. Cells 2021;11:61. [PMID: 35011625 DOI: 10.3390/cells11010061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Pan Z, Zhu T, Liu Y, Zhang N. Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases. Front Immunol 2022;13:850998. [DOI: 10.3389/fimmu.2022.850998] [Reference Citation Analysis]
37 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
38 Tian S, Liu Y, Sun K, Zhou X, Ma S, Zhang M, Zhou X, Wang L, Han Y. A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis. J Clin Lab Anal 2020;34:e23501. [PMID: 32915500 DOI: 10.1002/jcla.23501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
40 Feng SL, Zhang J, Jin H, Zhu WT, Yuan Z. A Network Pharmacology Study of the Molecular Mechanisms of Hypericum japonicum in the Treatment of Cholestatic Hepatitis with Validation in an Alpha-Naphthylisothiocyanate (ANIT) Hepatotoxicity Rat Model. Med Sci Monit 2021;27:e928402. [PMID: 33657087 DOI: 10.12659/MSM.928402] [Reference Citation Analysis]
41 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci 2020;21:E5097. [PMID: 32707678 DOI: 10.3390/ijms21145097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Cha HJ, Hwang J, Lee LE, Park Y, Song JJ. The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease. PLoS One 2021;16:e0244950. [PMID: 33411840 DOI: 10.1371/journal.pone.0244950] [Reference Citation Analysis]
43 Brevini T, Tysoe OC, Sampaziotis F. Tissue engineering of the biliary tract and modelling of cholestatic disorders. Journal of Hepatology 2020;73:918-32. [DOI: 10.1016/j.jhep.2020.05.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Labiano I, Agirre-Lizaso A, Olaizola P, Echebarria A, Huici-Izagirre M, Olaizola I, Esparza-Baquer A, Sharif O, Hijona E, Milkiewicz P, Milkiewicz M, González-Romero F, Aspichueta P, Monte MJ, Marin JJG, Vucur M, Luedde T, Marzioni M, Mann DA, Bujanda L, Rodrigues PM, Banales JM, Perugorria MJ. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. J Hepatol 2022:S0168-8278(22)00372-5. [PMID: 35750136 DOI: 10.1016/j.jhep.2022.05.044] [Reference Citation Analysis]
45 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Amirneni S, Haep N, Gad MA, Soto-Gutierrez A, Squires JE, Florentino RM. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol 2020; 26(47): 7470-7484 [PMID: 33384548 DOI: 10.3748/wjg.v26.i47.7470] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
47 Chang HJ, Zúñiga A, Conejero I, Voyvodic PL, Gracy J, Fajardo-Ruiz E, Cohen-Gonsaud M, Cambray G, Pageaux GP, Meszaros M, Meunier L, Bonnet J. Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples. Nat Commun 2021;12:5216. [PMID: 34471137 DOI: 10.1038/s41467-021-25538-y] [Reference Citation Analysis]
48 Costa V, Moreira M, Costa R, Fontes J. Primary Biliary Cholangitis Overlap With Autoimmune Hepatitis? A Case Report. J Med Cases 2021;12:131-3. [PMID: 34434444 DOI: 10.14740/jmc3623] [Reference Citation Analysis]
49 Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151-166. [PMID: 33128017 DOI: 10.1038/s41575-020-00372-7] [Cited by in Crossref: 164] [Cited by in F6Publishing: 133] [Article Influence: 82.0] [Reference Citation Analysis]
50 Prieto J, Banales JM, Medina JF. Primary biliary cholangitis: pathogenic mechanisms. Curr Opin Gastroenterol 2021;37:91-8. [PMID: 33332913 DOI: 10.1097/MOG.0000000000000703] [Reference Citation Analysis]
51 Lee EY, Song C. Immediate hypersensitivity reaction followed by successful oral desensitization to ursodiol. Allergy Asthma Clin Immunol 2021;17:75. [PMID: 34294117 DOI: 10.1186/s13223-021-00578-7] [Reference Citation Analysis]
52 Wang MN, Yu HT, Li YQ, Zeng Y, Yang S, Yang GP, Pei Q, Huang J. Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions. Drug Des Devel Ther 2021;15:185-93. [PMID: 33469270 DOI: 10.2147/DDDT.S289016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Grobe S, Badenhorst CPS, Bayer T, Hamnevik E, Wu S, Grathwol CW, Link A, Koban S, Brundiek H, Großjohann B, Bornscheuer UT. Engineering Regioselectivity of a P450 Monooxygenase Enables the Synthesis of Ursodeoxycholic Acid via 7β-Hydroxylation of Lithocholic Acid. Angew Chem Int Ed Engl 2021;60:753-7. [PMID: 33085147 DOI: 10.1002/anie.202012675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
54 Huang C, Xing X, Xiang X, Fan X, Men R, Ye T, Yang L. MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets. Biomed Pharmacother 2020;130:110558. [PMID: 32781357 DOI: 10.1016/j.biopha.2020.110558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]